| Q39810447 | A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients |
| Q34987555 | Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting |
| Q39275766 | Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. |
| Q42876596 | Determination of casopitant and its three major metabolites in dog and rat plasma by positive ion liquid chromatography/tandem mass spectrometry |
| Q34103300 | Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin |
| Q83045032 | Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist |
| Q43177434 | Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist |
| Q26997344 | Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis |
| Q38217456 | Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors |
| Q37332618 | Opportunities for the replacement of animals in the study of nausea and vomiting |
| Q51840084 | The potential role for corticosterone in the induction of cleft palate in mice after treatment with a selective NK-1 receptor antagonist, casopitant (GW679769B). |
| Q49264439 | The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting |
| Q82067204 | Tissue Distribution and Characterization of Drug-Related Material in Rats and Dogs after Repeated Oral Administration of Casopitant |